ABBV240920C187500
- 8.08
- 0.000.00%
AbbVie Newsroom
Competitor Analysis: Evaluating AbbVie And Competitors In Biotechnology Industry
Investors in AbbVie (NYSE:ABBV) Have Seen Strong Returns of 225% Over the Past Five Years
Unmissable investment strategy! The Federal Reserve officially enters a new era of interest rate cuts, these 6 industries have the most profitable potential.
Prepare yourself for the interest rate cut cycle.
BeiGene Initiated at Outperform at JMP Securities on Strength of Brukinsa
Susan G. Komen to Host MORE THAN PINK Walk in the Bay Area This Fall
AbbVie (NYSE:ABBV) Expands Eye Care Portfolio With Ripple Therapeutics Collaboration, Boosts Growth Potential
AbbVie Inc. (NYSE:ABBV) Is Largely Controlled by Institutional Shareholders Who Own 73% of the Company
Abbie Inc.(ABBV) Stocks Elliott Wave Technical Analysis [Video]
AbbVie (ABBV) Stock Dips While Market Gains: Key Facts
Express News | Ripple Therapeutics: Eligible to Receive up to $290 Mln in Option Fees & Milestones, Tiered Royalties on Net Sales
Express News | Ripple Therapeutics: Will Receive an Upfront Payment of $21.8 Mln From Abbvie
Express News | Ripple Therapeutics: To Develop Rtc-620 for Glaucoma Management
Ripple Therapeutics Announces Collaboration and Option-to-License Agreement With AbbVie to Develop Next-Generation Therapies for Glaucoma Management
TransDigm, BJ's Wholesale, AbbVie And More On CNBC's 'Final Trades'
Can AbbVie Regain Its Status As a Top Dividend Growth Stock?
Eli Lilly and AbbVie: J.P. Morgan Selects the Top Large-Cap Pharma Stocks to Buy
AbbVie (ABBV) Is Considered a Good Investment by Brokers: Is That True?
DBS Initiates AbbVie(ABBV.US) With Hold Rating
DBS analyst Mark Kong CFA initiates coverage on $AbbVie(ABBV.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 0.0% and a total average return of 0.0% over the
Maintaining a Hold: Balancing AbbVie's Strategic Successes Against Market Challenges
Latitude Expands Midwest Presence With New Chicago Office